Impact of COVID-19 on the occurrence and exacerbation of cutaneous forms of lupus erythematosus: A review

Cover Page

Cite item

Full Text

Abstract

The article addresses the impact of the new coronavirus infection on the occurrence of cutaneous forms of lupus erythematosus (LE). Since the beginning of the COVID-19 pandemic, there has been an increase in the incidence of cutaneous LE worldwide, the emergence of new cases, and exacerbation and aggravation of the severity of existing ones. The pathogenesis of cutaneous LE, and the role of viral infections in its occurrence, mainly COVID-19, is reviewed. The need for the SARS-CoV-2 vaccination and its potential as a possible trigger is described. It is necessary to note the importance of clinicians in diagnosing LE since it is essential for the dermatologist to know the features of its course and be able to suspect and diagnose even the rarest forms of this disease. Proper awareness and correct diagnosis determine the optimal drug therapy and patient health in the future.

About the authors

Eleonora S. Mikheeva

People’s Friendship University of Russia (RUDN University)

Email: marykor@bk.ru
ORCID iD: 0000-0001-8934-3197

Graduate Student

Russian Federation, Moscow

Iuliia M. Golubeva

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology

Email: marykor@bk.ru
ORCID iD: 0000-0003-2047-7925

Dermatologist

Russian Federation, Moscow

Ekaterina E. Radionova

Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology

Email: marykor@bk.ru
ORCID iD: 0000-0002-2642-9126

Cand. Sci. (Med.)

Russian Federation, Moscow

Olga V. Zhukova

People’s Friendship University of Russia (RUDN University); Moscow Scientific and Practical Center for Dermatovenereology and Cosmetology

Email: marykor@bk.ru
ORCID iD: 0000-0001-5723-6573

D. Sci. (Med.), Prof.

Russian Federation, Moscow; Moscow

Irina M. Korsunskaya

Center for Theoretical Problems of Physical and Chemical Pharmacology

Author for correspondence.
Email: marykor@bk.ru
ORCID iD: 0000-0002-6583-0318

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Joo YB, Lim YH, Kim KJ, et al. Respiratory viral infections and the risk of rheumatoid arthritis. Arthritis Res Ther. 2019;21(1):199.
  2. Gartshteyn Y, Askanase AD, Schmidt NM, et al. COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol. 2020;2(8):e452-4.
  3. Illescas-Montes R, Corona-Castro CC, Melguizo-Rodríguez L, et al. Infectious processes and systemic lupus erythematosus. Immunology. 2019;158(3):153-60. doi: 10.1111/imm.13103
  4. Dorgham DA, Anwar S, Khaled AS. Infection in systemic lupus erythematosus patients. Egypt Rheumatol. 2021;43(2):115-8.
  5. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8.
  6. Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID- 19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;S0190-9622(20):32126-5.
  7. Caso F, Costa L, Ruscitti P, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524. doi: 10.1016/j.autrev.2020.102524
  8. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5
  9. Aringer M, Stummvoll GH, Steiner G, et al. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford). 2001;40(8):876-81. doi: 10.1093/rheumatology/40.8.876
  10. Collins CE, Gavin AL, Migone TS, et al. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8(1):R6. doi: 10.1186/ar1855
  11. Rönnelid J, Tejde A, Mathsson L, et al. Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE. Ann Rheum Dis. 2003;62(1):37-42. doi: 10.1136/ard.62.1.37
  12. Zamani B, Moeini Taba SM, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: a case report. J Med Case Rep. 2021;15(1):29.
  13. Gracia-Ramos AE, Saavedra-Salinas MÁ. Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatol Int. 2021;41(4):799-809.
  14. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876-86.
  15. Gambichler T, Scholl L, Dickel H, et al. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2021;35:e415-6.
  16. Niebel D, Ralser-Isselstein V, Jaschke K, et al. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine. Dermatol Ther. 2021;34:e15017.
  17. Kreuter A, Burmann SN, Burckert B, et al. Transition of cutaneous into systemic lupus erythematosus following adenoviral vector based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol. 2021;35(11):e733-5. doi: 10.1111/jdv.17514
  18. Liu V, Messenger NB. New-onset cutaneous lupus erythematosus after the COVID-19 vaccine. Dermatol Online J. 2021;27. doi: 10.5070/D3271156093
  19. Am N, Saleh AM, Khalid A, et al. Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review. Clin Rheumatol. 2022;17:1-6.
  20. Kreuter A, Licciardi-Fernandez MJ, Burmann SN, et al. Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA-based or adenoviral vector-based SARS-CoV-2 vaccination. Clin Exp Dermatol. 2022;47:161-3.
  21. Joseph AK, Chong BF. Subacute cutaneous lupus erythematosus flare triggered by COVID-19 vaccine. Dermatol Ther. 2021;34:e15114.
  22. Lemoine C, Padilla C, Krampe N, et al. Systemic lupus erythematous after Pfizer COVID-19 vaccine: a case report. Clin Rheumatol. 2022;16:1-5. doi: 10.1007/s10067-022-06126-x
  23. Raviv Y, Betesh-Abay B, Valdman-Grinshpoun Y, et al. First presentation of systemic lupus erythematosus in a 24-year-old male following mRNA COVID-19 vaccine. Case Rep Rheumatol. 2022;2022:9698138.
  24. Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol. 2021;3:e613-5.
  25. Barbhaiya M, Levine JM, Siegel CH, et al. Adverse events and disease flares after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol. 2021;30:1-4.
  26. van der Laan JW, Gould S, Tanir JY. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine. 2015;33:1507-14. doi: 10.1016/j.vaccine.2015.01.073
  27. Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open. 2021;7:e001814. doi: 10.1136/rmdopen-2021-001814
  28. Izmirly PM, Kim MY, Samanovic M, et al. Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-CoV-2 vaccination. Arthritis Rheumatol. 2021;74:284-94. doi: 10.1002/art.41937
  29. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81:695-709. doi: 10.1136/annrheumdis-2021-221490
  30. Moyon Q, Sterlin D, Miyara M, et al. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Ann Rheum Dis. 2022;81:575-83. doi: 10.1136/annrheumdis-2021-221097
  31. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79:39-52. doi: 10.1136/annrheumdis-2019-215882
  32. Ferri C, Ursini F, Gragnani L, et al. Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups. J Autoimmun. 2021;125:102744. doi: 10.1016/j.jaut.2021.102744

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1

Download (197KB)
Indexing metadata
3. Fig. 2

Download (197KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies